Tag: Liver

All patients had initial objective response and 90 percent had sustained complete response; few patients had high-grade adverse events

Black patients also more likely to report limitations in daily living, instrumental activities of daily living

Overall survival, but not progression-free survival, improved with tremelimumab plus durvalumab versus sorafenib for unresectable HCC

EBRT strongly recommended as potential first-line therapy for patients with HCC confined to liver who are not candidates for curative therapy

Increased risk for hepatocellular carcinoma also seen with higher transferrin saturation levels in patients with nonalcoholic fatty liver disease

Incidence of liver cancer rising at an annual rate of 5.7 percent in rural areas

Amount of alcohol consumed in each occasion seems to be a less important risk factor

Mortality higher for patients readmitted to outside hospital rather than index hospital after hepatopancreatobiliary or gastric cancer surgery

Black patients have better liver function at the time of hepatocellular carcinoma diagnosis; have less early-stage HCC, larger tumors

Risk for incident primary hepatic malignancy and death increased among men with HFE p.C282Y homozygosity